Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Ann Surg. 2020 Jun;271(6):1072–1079. doi: 10.1097/SLA.0000000000003124

TABLE 1.

Patient Characteristics and Comprehensive VTE Chemoprophylaxis Failure Rates

Patient Characteristic Patients n (%) Any VTE Chemoprophylaxis Failure* n (%) P Value

Overall 4086 (100) 734 (18.0)
Age 0.49
 ≤40 yrs   351 (8.6) 100 (28.5)
 41–60 yrs 1,378 (33.7) 256 (18.6)
 61–74 yrs 1430 (35.0) 223 (15.6)
 ≥75 yrs   927 (22.7) 155 (16.7)
Sex 0.85
 Male 1911 (46.8) 352 (18.4)
 Female 2175 (53.2) 382 (17.6)
Race 0.58
 Asian   103 (2.5)   15 (14.6)
 African American   482 (11.8) 127 (26.3)
 White 3294 (80.6) 553 (16.8)
 Other/unknown 207 (5.1)   39 (18.8)
Body Mass Index 0.79
 Underweight   141 (3.5)   34 (24.1)
 Normal 1172 (28.7) 226 (19.3)
 Overweight/obese 2773 (67.9) 474 (17.1)
Diabetes 0.77
 Yes   637 (15.6) 105 (16.5)
 No 3449 (84.4) 629 (18.2)
Comorbidities 0.96
 0   985 (24.1) 157 (15.9)
 1 1406 (34.4) 257 (18.3)
 2   905 (22.2) 174 (19.2)
 ≥3   790 (19.3) 146 (18.5)
Active smoker 0.98
 Yes   746 (18.3) 135 (18.1)
 No 3340 (81.7) 599 (17.9)
Surgical indication 0.28
 Neoplasm 1935 (47.4) 299 (15.5)
 Benign 2151 (52.6) 435 (20.2)
Elective surgery 0.19
 Yes 2741 (67.1) 437 (15.9)
 No 1345 (32.9) 297 (22.1)
Length of Stay (LOS) 0.15
 Quartile 1 (≤3 d)   957 (23.4) 105 (11.0)
 Quartile 2 (4–5 d) 1239 (30.3) 207 (16.7)
 Quartile 3 (6–8 d)   974 (23.8) 185 (19.0)
 Quartile 4 (≥9 d)   915 (22.4) 237 (25.9)
 Median LOS, d (IQR)       5 (4–8)
*

Patients that failed comprehensive VTE chemoprophylaxis for any reason. The percentage is out of the total patients in the corresponding subgroup.

Clustered chi-square test of association.